Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
NEW YORK, Feb. 17, 2016 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its fourth quarter and full year 2015 financial results prior to the NASDAQ market open on Tuesday, February 23, 2016. Intercept management will conduct a conference call and audio webcast on Tuesday, February 23, 2016 at 8:00 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- Cowen 36th Annual Health Care Conference on Monday, March 7, 2016 at 1:20 p.m. Eastern Time
Webcast information for these events will be available on Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic non-viral, progressive liver diseases. The Company's lead product candidate, obeticholic acid (OCA), is an farnesoid X receptor (FXR) agonist. OCA is being developed to treat a variety of chronic liver diseases, including primary biliary cirrhosis, renamed primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with liver fibrosis and granted OCA fast track designation for the treatment of patients with PBC. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. Intercept's pipeline of product candidates includes other novel bile acid analogs such as INT-767, which is in clinical development. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
